Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Nottingham
About this trial
Colorectal cancer is the fourth most common cancer in the UK. Prehabilitation, including exercise, can improve recovery from surgery. This pilot study investigates the combined effects of resistance and high-intensity interval training (ReHIIT) in healthy adults to establish baseline physiology and responses for comparison with cancer patients
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participant is willing and able to give informed consent for participation in the study.
Availability and willingness to attend the Royal Derby Hospital site for a minimum of 8 exercise sessions and 2 assessment sessions across the study period.
Disqualifiers
BMI <18 or >35 kg/m2
Known active cance
Known metabolic disease
Current known neurological or musculoskeletal conditions (e.g. epilepsy)
Trial design
Design model
Single group
Treatments tested in this trial
ReHIIT Training Intervention
Other interventionParticipants will complete 8-12 supervised sessions combining high-intensity interval cycling (5 × 1-minute intervals at 110% CPET wattage, with 90-second rest intervals) and resistance training at 70% 1-RM (3 sets of 8-12 repetitions, 6 exercises).
Treatment groups
14 Participants
are divided into 1 treatment groupGroup A: Resistance exercise training plus high-intensity interval training (ReHIIT) InterventionExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in anaerobic threshold (CPET-derived)
Time frame
From baseline to 4-weeks after the start of the intervention2
Change in Muscle mass
Derived from DXA and stable isotope assessments of muscle mass (COSIAM, Cegielski et al., 2021)
Time frame
From baseline to 4-weeks after the start of the interventionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov